Instrumento Inactivo

Otros idiomas AgeX Therapeutics, Inc.

Acciones

AGE

US00848H2076

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	26/03
AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results	22/03
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	27/02
AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee	11/01
AgeX Therapeutics : New Financial Obligation - Form 8-K	28/12
AgeX Therapeutics : Termination of Material Agreement - Form 8-K	01/12
Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023	01/12
Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology	17/11
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000	14/11
AgeX Therapeutics Reports Third Quarter 2023 Financial Results	14/11
AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
AgeX Therapeutics : New Financial Obligation - Form 8-K	06/10/23
AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company	08/09/23
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	06/09/23
AGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AgeX Therapeutics, Inc. Is Fair to Shareholders	30/08/23
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement	30/08/23
Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.	30/08/23
AgeX Therapeutics : New Financial Obligation - Form 8-K	25/08/23
Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000	14/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas AgeX Therapeutics, Inc.

Acciones

AGE

US00848H2076

Otros idiomas

Filtros